Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Star Combo Pharma Ltd. ( (AU:S66) ) has shared an announcement.
Star Combo Pharma Ltd announced the results of its 2025 Annual General Meeting, where shareholders approved the adoption of the Remuneration Report and the re-election of Ms. Wei Han as a director. These resolutions were carried with overwhelming support, indicating strong shareholder confidence in the company’s leadership and strategic direction. This outcome is likely to reinforce Star Combo’s stability and continued growth in the health and beauty industry.
The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.
More about Star Combo Pharma Ltd.
Star Combo Pharma Ltd is a leading distributor and manufacturer of branded premium health and natural beauty products based in Sydney. The company distributes its products locally in Australia and overseas, with significant operations in China. Star Combo supplies Australian pharmacy lines and has distribution agreements with over 450 Terry White and Symbion Chemists, focusing on health products made from natural ingredients.
Average Trading Volume: 22,765
Technical Sentiment Signal: Buy
Current Market Cap: A$29.03M
Learn more about S66 stock on TipRanks’ Stock Analysis page.